2012;110:562 7. 12. Weiss A, Brose S, Ploetze K, et al. Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: which dose regimen should be preferred? Clin Hemorheol Micro- circ. 2013;54:249 58. 13. Pengo V, Palareti G, Cucchini U, et al. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LI- WACAP). Clin Appl Thromb Hemost. 2007;13:241 8. 14. Hjellstrom L, Labaf A. Prophylactic doses of low-molecular weight hepa- rin as periprocedural bridging therapy in mechanical heart valve patients. Thromb Res. 2018;163:180 4. 15. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridg- ing anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823 33. CLINICAL STATEMENTS AND GUIDELINES 11.4. Excessive Anticoagulation and Serious Bleeding With Prosthetic Valves 1. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511 20. 2. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413 24. 3. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131 41. 4. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andex- anet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326 35. 5. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran rever- sal - full cohort analysis. N Engl J Med. 2017;377:431 41. 6. Genewein U, Haeberli A, Straub PW, et al. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol. 1996;92:479 85. 7. 